Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Revenue (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed Revenue for 9 consecutive years, with $57.6 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 23.93% to $57.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $236.2 million through Dec 2025, up 47.46% year-over-year, with the annual reading at $236.2 million for FY2025, 47.46% up from the prior year.
  • Revenue for Q4 2025 was $57.6 million at Akebia Therapeutics, down from $58.8 million in the prior quarter.
  • The five-year high for Revenue was $62.5 million in Q2 2025, with the low at $394000.0 in Q2 2022.
  • Average Revenue over 5 years is $41.2 million, with a median of $46.5 million recorded in 2024.
  • The sharpest move saw Revenue tumbled 99.26% in 2022, then skyrocketed 14208.63% in 2023.
  • Over 5 years, Revenue stood at $1.2 million in 2021, then skyrocketed by 150.0% to $3.0 million in 2022, then surged by 1301.53% to $42.0 million in 2023, then rose by 10.59% to $46.5 million in 2024, then rose by 23.93% to $57.6 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $57.6 million, $58.8 million, and $62.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.